Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer

PartnershipRupitasertibSelective Estrogen Receptor DegraderPositive

AI Analysis

Summary

Evexta Bio announced a clinical trial collaboration and supply agreement with Roche to evaluate Rupitasertib combined with a selective estrogen receptor degrader in patients with advanced/metastatic breast cancer.

Clinical Trial Data

Importance:5/10

Sentiment:

0.30

collaborationpartnershipclinical trialbreast cancercombination therapy

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on August 4, 2026 7:00 AM

Read Original